{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T15:55:15Z","timestamp":1785858915070,"version":"3.56.0"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2005,9]]},"DOI":"10.1097\/01.crd.0000137255.54390.12","type":"journal-article","created":{"date-parts":[[2005,8,16]],"date-time":"2005-08-16T04:01:08Z","timestamp":1124164868000},"page":"240-246","source":"Crossref","is-referenced-by-count":36,"title":["Peroxisome Proliferator-Activated Receptor-Alpha and Atherosclerosis"],"prefix":"10.1097","volume":"13","author":[{"given":"Zarmen","family":"Israelian-Konaraki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter D.","family":"Reaven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-4-20210203","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1177\/174182670100800404","article-title":"Peroxisome proliferator-activated receptors (PPARs) and their role in the vessel wall: possible mediators of cardiovascular risk?","volume":"8","author":"Marx","year":"2001","journal-title":"J Cardiovasc Risk"},{"key":"R2-4-20210203","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/S0006-2952(00)00430-5","article-title":"Role of peroxisome proliferator-activated receptors (PPAR) in atherosclerosis.","volume":"60","author":"Neve","year":"2000","journal-title":"Biochem Pharmacol"},{"key":"R3-4-20210203","first-page":"27","article-title":"Lipids and Vascular Disease\u2014Current Issues.","author":"Staels","year":"2001"},{"key":"R4-4-20210203","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1073\/pnas.0538015100","article-title":"Lipolysis of triglyceride-rich lipoproteins generates PPAR ligands: evidence for anti-inflammatory role for lipoprotein lipase.","volume":"100","author":"Ziouzenkova","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R5-4-20210203","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s11883-001-0015-x","article-title":"The role of fibric acids in atherosclerosis.","volume":"3","author":"Fruchart","year":"2001","journal-title":"Current Atheroscler Rep"},{"key":"R6-4-20210203","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1097\/00024382-200208000-00001","article-title":"NF-\u03baB Activation and inhibition: a review.","volume":"18","author":"Sun","year":"2002","journal-title":"Shock"},{"key":"R7-4-20210203","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1677\/joe.0.1690447","article-title":"AP-1-Glucocorticoid receptor crosstalk taken to higher level.","volume":"169","author":"Karin","year":"2001","journal-title":"J Endocrinol"},{"key":"R8-4-20210203","first-page":"178","article-title":"Transcription factors as activators of gene transcription: AP-1 and NF-kappa B.","volume":"52","author":"Adcock","year":"1997","journal-title":"Monaldi Arch Chest Dis"},{"key":"R9-4-20210203","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1182\/blood-2002-06-1762","article-title":"Fibrates down-regulate IL-1-stimulated C-reactive protein gene expression in hepatocytes by reducing nuclear p50-NF\u03baB-C\/EBP-\u03b2 complex formation.","volume":"101","author":"Kleeman","year":"2003","journal-title":"Blood"},{"key":"R10-4-20210203","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1161\/hh2101.099270","article-title":"Novel clinical markers of vascular wall inflammation.","volume":"89","author":"Blake","year":"2001","journal-title":"Circ Res"},{"key":"R11-4-20210203","doi-asserted-by":"crossref","first-page":"33471","DOI":"10.1074\/jbc.M102839200","article-title":"Negative regulation of human fibrinogen gene expression by peroxisome proliferator-activated receptor \u03b1 agonists via inhibition of CCAAT box\/enhancer-binding protein \u03b2.","volume":"276","author":"Gervois","year":"2001","journal-title":"J Biol Chem"},{"key":"R12-4-20210203","first-page":"822","article-title":"Peroxisome proliferator-activated receptor activation inhibit oxidized low-density lipoprotein-induced endothelin-1 secretion in endothelial cells.","volume":"40","author":"Martin-Nizard","year":"2000","journal-title":"J Cardiovasc Risk"},{"key":"R13-4-20210203","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1097\/00041433-200110000-00006","article-title":"Peroxisome proliferator-activated receptors in endothelial cell biology.","volume":"12","author":"Plutzky","year":"2001","journal-title":"Curr Opin Lipidol"},{"key":"R14-4-20210203","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1161\/01.CIR.103.21.2531","article-title":"Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerotic drugs.","volume":"103","author":"Pasceri","year":"2001","journal-title":"Circulation"},{"key":"R15-4-20210203","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1038\/31701","article-title":"Activation of human aortic smooth-muscle cells is inhibited by PPAR-\u03b1 but not PPAR-\u03b3 activators.","volume":"25","author":"Staels","year":"1998","journal-title":"Nature"},{"key":"R16-4-20210203","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1097\/00043798-200108000-00002","article-title":"PPAR's in inflammation, atherosclerosis and thrombosis.","volume":"8","author":"Duez","year":"2001","journal-title":"J Cardiovasc Risk"},{"key":"R17-4-20210203","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1161\/01.CIR.103.2.207","article-title":"PPAR-\u03b1 agonists inhibit tissue factor expression in human monocytes and macrophages.","volume":"16","author":"Neve","year":"2001","journal-title":"Circulation"},{"key":"R18-4-20210203","doi-asserted-by":"crossref","first-page":"3125","DOI":"10.1161\/01.CIR.99.24.3125","article-title":"PPAR-\u03b1 activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells.","volume":"99","author":"Marx","year":"1999","journal-title":"Circulation"},{"key":"R19-4-20210203","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1161\/01.RES.0000014225.20727.8F","article-title":"PPAR activators as anti-inflammatory mediators in human T lymphocytes.","volume":"90","author":"Marx","year":"2002","journal-title":"Circ Res"},{"key":"R20-4-20210203","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1001\/archinte.162.22.2597","article-title":"Diabetic, plasma insulin, and cardiovascular disease. Subgroup analysis from the Department of Veterans Affairs. High-Density Lipoprotein Intervention Trial (VA-HIT).","volume":"162","author":"Rubin","year":"2002","journal-title":"Arch Intern Med"},{"key":"R21-4-20210203","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.2337\/diacare.26.5.1513","article-title":"Insulin resistance and cardiovascular events with low HDL cholesterol. The Veterans Affairs HDL Intervention Trial (VA-HIT).","volume":"26","author":"Robins","year":"2003","journal-title":"Diabetes Care"},{"key":"R22-4-20210203","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1161\/01.CIR.92.7.1779","article-title":"Some coronary risk factors related to insulin resistance syndrome and treatment with gemfibrozil. Experience from the Helsinki Heart Study.","volume":"92","author":"Tenkanen","year":"1995","journal-title":"Circulation"},{"key":"R23-4-20210203","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/S0140-6736(00)04209-4","article-title":"(Diabetes Atherosclerosis Intervention Study Investigators). Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: Diabetes Atherosclerosis Intervention Study, a randomized study.","volume":"357","author":"Steiner","year":"2001","journal-title":"Lancet"},{"key":"R24-4-20210203","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1161\/01.CIR.102.1.21","article-title":"Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. The Bezafibrate Infarction Prevention (BIP) Study.","volume":"102","year":"2000","journal-title":"Circulation"},{"key":"R25-4-20210203","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1016\/S0735-1097(98)00442-2","article-title":"Treatment effects on serum lipoprotein lipids, apolipoproteins and low density lipoprotein particle size and relationships of lipoprotein variables to progression of coronary artery disease in the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT).","volume":"32","author":"Ruotolo","year":"1998","journal-title":"J Am Coll Cardiol"}],"container-title":["Cardiology in Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/01.crd.0000137255.54390.12","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T14:59:19Z","timestamp":1785855559000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00045415-200509000-00004"}},"subtitle":["From Basic Mechanisms to Clinical Implications"],"short-title":[],"issued":{"date-parts":[[2005,9]]},"references-count":25,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2005]]}},"URL":"https:\/\/doi.org\/10.1097\/01.crd.0000137255.54390.12","relation":{},"ISSN":["1061-5377"],"issn-type":[{"value":"1061-5377","type":"print"}],"subject":[],"published":{"date-parts":[[2005,9]]}}}